Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.
作者信息
Rizzo Jason M, Fecher Leslie A, Chan May P, Durham Alison B
机构信息
Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan.
Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
出版信息
JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May.
Abstract
摘要
相似文献
1
Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.
JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May.
2
The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.
3
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.
4
Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Drugs Today (Barc). 2015 Sep;51(9):549-58. doi: 10.1358/dot.2015.51.9.2383044.
5
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Ann Pharmacother. 2017 Aug;51(8):675-681. doi: 10.1177/1060028017702654. Epub 2017 Mar 28.
6
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.
J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.
7
An evaluation of talimogene laherparepvec for the treatment of melanoma.
Expert Opin Biol Ther. 2020 Jan;20(1):9-14. doi: 10.1080/14712598.2020.1689951.
8
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Melanoma Res. 2018 Jun;28(3):250-255. doi: 10.1097/CMR.0000000000000444.
9
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017.
10
Pharmacy Operationalization of the Intralesional Oncolytic Immunotherapy Talimogene Laherparepvec.
Hosp Pharm. 2018 Oct;53(5):296-302. doi: 10.1177/0018578717749926. Epub 2018 Jan 10.
引用本文的文献
1
Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment.
J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005257.
本文引用的文献
1
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 2017 Oct 5.
2
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.
3
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Onco Targets Ther. 2016 Nov 16;9:7081-7093. doi: 10.2147/OTT.S115245. eCollection 2016.
4
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.
J Immunother Cancer. 2016 Sep 20;4:53. doi: 10.1186/s40425-016-0158-5. eCollection 2016.
5
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
Ann Surg Oncol. 2016 Dec;23(13):4169-4177. doi: 10.1245/s10434-016-5286-0. Epub 2016 Jun 24.
6
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
7
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Ann Surg Oncol. 2010 Mar;17(3):718-30. doi: 10.1245/s10434-009-0809-6.
8
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
9
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Clin Cancer Res. 2006 Nov 15;12(22):6737-47. doi: 10.1158/1078-0432.CCR-06-0759.
Zotero 插件